AstraZeneca Enters Multi-Year Genomics Agreement With Helix for Drug Discovery Research
MT Newswires Live
Jul 07
AstraZeneca (AZN) has entered a multi-year agreement to access Helix's genomic datasets to support research for drug discovery and development, Helix said Tuesday.
Under the agreement, AstraZeneca will gain access to Helix's GenoSphere cohorts, which combine Exome+ genomic sequencing and longitudinal clinical data across multiple disease areas, including cardiometabolic, respiratory and autoimmune disorders, among others, the company said.
Financial terms of the deal were not disclosed.
Shares of AstraZeneca were 1.3% higher in early Tuesday trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.